Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Publications

Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

PMID: 24744161
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2014
Reference: Cancer Chemother Pharmacol. 2014 Jun;73(6):1205-15. doi: 10.1007/s00280-014-2457-1. Epub 2014 Apr 18.
Impact factor:
Publication type: Paper in international publication
Authors: Aguirre, Elena; Benhadji, Karim A; Callies, Sophie; Garcia, Margarita; Gil-Martin, Marta; Llombart, Antonio; Morales, Serafin; Oaknin, Ana; Salazar, Ramon; Wickremsinhe, Enaksha R et al.
DOI: 10.1007/s00280-014-2457-1

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID: 24652201
Journal: INVEST NEW DRUG
Year: 2014
Reference: Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21.
Impact factor: 2.927
Publication type: Paper in international publication
Authors: Brana, Irene, Siu, Lillian L, De Jonge, Maja J, Homji, Natasha, Mills, David, Di Tomaso, Emmanuelle, Sarr, Celine, Trandafir, Lucia, Massacesi, Cristian, Eskens, Ferry et al.
DOI: 10.1007/s10637-014-0082-9

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID: 24652201
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2014
Reference: Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21.
Impact factor:
Publication type: Paper in international publication
Authors: Bendell, Johanna C; Brana, Irene; De Jonge, Maja J; Di Tomaso, Emmanuelle; Eskens, Ferry; Homji, Natasha; Massacesi, Cristian; Mills, David; Rodon, Jordi; Sarr, Celine et al.
DOI: 10.1007/s10637-014-0082-9

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

PMID: 24496004
Journal: J THORAC ONCOL
Year: 2014
Reference: J Thorac Oncol. 2014 Mar;9(3):316-23. doi: 10.1097/JTO.0000000000000088.
Impact factor: 5.8
Publication type: Paper in international publication
Authors: Felip, Enriqueta, Martinez, Pablo, Janne, Pasi A, Cohen, Roger B, Laird, A Douglas, Mace, Sandrine, Engelman, Jeffrey A, Ruiz-Soto, Rodrigo, Rockich, Kevin, Xu, Jianbo et al.
DOI: 10.1097/JTO.0000000000000088

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

PMID: 24496004
Journal: Journal of Thoracic Oncology
Year: 2014
Reference: J Thorac Oncol. 2014 Mar;9(3):316-23. doi: 10.1097/JTO.0000000000000088.
Impact factor:
Publication type: Paper in international publication
Authors: Cohen, Roger B; Engelman, Jeffrey A; Felip, Enriqueta; Janne, Pasi A; Laird, A Douglas; Mace, Sandrine; Martinez, Pablo; Rockich, Kevin; Ruiz-Soto, Rodrigo; Shapiro, Geoffrey I et al.
DOI: 10.1097/JTO.0000000000000088

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

PMID: 24583798
Journal: CLIN CANCER RES
Year: 2014
Reference: Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.
Impact factor: 8.193
Publication type: Paper in international publication
Authors: Papadopoulos, Kyriakos P, Tabernero, Josep, Markman, Ben, Patnaik, Amita, Tolcher, Anthony W, Baselga, Jose, Shi, Weiliang, Egile, Coumaran, Ruiz-Soto, Rodrigo, Laird, A Douglas et al.
DOI: 10.1158/1078-0432.CCR-13-2403

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

PMID: 24583798
Journal: CLINICAL CANCER RESEARCH
Year: 2014
Reference: Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.
Impact factor:
Publication type: Paper in international publication
Authors: Baselga, Jose; Egile, Coumaran; Laird, A Douglas; Lorusso, Patricia M; Markman, Ben; Miles, Dale; Papadopoulos, Kyriakos P; Patnaik, Amita; Ruiz-Soto, Rodrigo; Shi, Weiliang et al.
DOI: 10.1158/1078-0432.CCR-13-2403

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

PMID: 25142843
Journal: ONCOLOGIST
Year: 2014
Reference: Oncologist. 2014 Sep;19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20.
Impact factor: 4.54
Publication type: Paper in international publication
Authors: Suarez, Cristina, Bellmunt, Joaquim, Pons, Francesc, Bonfill, Teresa, Beltran, Marta, Moya, Irene, Galtes, Susana, Albanell, Joan, Carles, Joan, Rodon, Jordi et al.
DOI: 10.1634/theoncologist.2014-0072

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

PMID: 25142843
Journal: ONCOLOGIST
Year: 2014
Reference: Oncologist. 2014 Sep;19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20.
Impact factor:
Publication type: Paper in international publication
Authors: Albanell, Joan; Bellmunt, Joaquim; Beltran, Marta; Bonfill, Teresa; Carles, Joan; Gallardo, Enrique; Galtes, Susana; Moya, Irene; Pons, Francesc; Rodon, Jordi et al.
DOI: 10.1634/theoncologist.2014-0072

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

PMID: 24827126
Journal: ANN ONCOL
Year: 2014
Reference: Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
Impact factor: 6.578
Publication type: Paper in international publication
Authors: Balmana, J, Tung, N M, Isakoff, S J, Grana, B, Ryan, P D, Saura, C, Lowe, E S, Frewer, P, Winer, E, Baselga, J et al.
DOI: 10.1093/annonc/mdu187

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

PMID: 24827126
Journal: ANNALS OF ONCOLOGY
Year: 2014
Reference: Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
Impact factor:
Publication type: Paper in international publication
Authors: Balmana, J; Baselga, J; Frewer, P; Garber, J E; Grana, B; Isakoff, S J; Lowe, E S; Ryan, P D; Saura, C; Tung, N M et al.
DOI: 10.1093/annonc/mdu187

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

PMID: 24470511
Journal: CLIN CANCER RES
Year: 2014
Reference: Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27.
Impact factor: 8.193
Publication type: Clinical Trials
Authors: Di Tomaso, Emmanuelle, Saura, Cristina, Bendell, Johanna, Jerusalem, Guy, Su, Shaun, Ru, Qinhua, De Buck, Stefan, Mills, David, Ruquet, Sophie, Bosch, Ana et al.
DOI: 10.1158/1078-0432.CCR-13-1070

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

PMID: 24470511
Journal: CLINICAL CANCER RESEARCH
Year: 2014
Reference: Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27.
Impact factor:
Publication type: Clinical Trials
Authors: Baselga, Jose; Beck, Joseph T; Bendell, Johanna; Bosch, Ana; De Buck, Stefan; Di Tomaso, Emmanuelle; Dirix, Luc; Hirawat, Samit; Jerusalem, Guy; Massacesi, Cristian et al.
DOI: 10.1158/1078-0432.CCR-13-1070

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

PMID: 24570330
Journal: CANCER CHEMOTH PHARM
Year: 2014
Reference: Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26.
Impact factor: 2.571
Publication type: Paper in international publication
Authors: Siguero, Mariano, Castellano, Daniel E, Bellmunt, Joaquim, Maroto, Jose Pablo, Font-Pous, Albert, Morales-Barrera, Rafael, Ghanem, Ismael, Suarez, Cristina, Martin Lorente, Cristina, Etxaniz, Olatz et al.
DOI: 10.1007/s00280-014-2419-7

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

PMID: 24570330
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2014
Reference: Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26.
Impact factor:
Publication type: Paper in international publication
Authors: Alfaro, Vicente; Bellmunt, Joaquim; Capdevila, Laia; Carles, Joan; Castellano, Daniel E; Coronado, Cinthya; Etxaniz, Olatz; Fernandez-Teruel, Carlos; Font-Pous, Albert; Ghanem, Ismael et al.
DOI: 10.1007/s00280-014-2419-7

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

PMID: 25270629
Journal: STROKE
Year: 2014
Reference: Stroke. 2014 Nov;45(11):3304-10. doi: 10.1161/STROKEAHA.114.005835. Epub 2014 Sep 30.
Impact factor: 6.018
Publication type: Clinical Trials
Authors: Urfer, Roman, Moebius, Hans J, Skoloudik, David, Santamarina, Estevo, Sato, Wakao, Mita, Shiro, Muir, Keith W et al.
DOI: 10.1161/STROKEAHA.114.005835

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

PMID: 25270629
Journal: STROKE
Year: 2014
Reference: Stroke. 2014 Nov;45(11):3304-10. doi: 10.1161/STROKEAHA.114.005835. Epub 2014 Sep 30.
Impact factor:
Publication type: Clinical Trials
Authors: Mita, Shiro; Moebius, Hans J; Muir, Keith W; Santamarina, Estevo; Sato, Wakao; Skoloudik, David; Urfer, Roman et al.
DOI: 10.1161/STROKEAHA.114.005835

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

PMID: 24081577
Journal: ANN HEMATOL
Year: 2014
Reference: Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1.
Impact factor: 2.396
Publication type: Clinical Trials
Authors: Martinez-Cuadron, David, Montesinos, Pau, Oriol, Albert, Salamero, Olga, Vidriales, Belen, Bergua, Juan, Herrera, Pilar, Vives, Susanna, Sanz, Jaime, Carpio, Cecilia et al.
DOI: 10.1007/s00277-013-1914-y

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

PMID: 24081577
Journal: ANNALS OF HEMATOLOGY
Year: 2014
Reference: Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1.
Impact factor:
Publication type: Clinical Trials
Authors: Bergua, Juan; Carpio, Cecilia; Herrera, Pilar; Martinez-Cuadron, David; Montesinos, Pau; Moscardo, Federico; Oriol, Albert; Rodriguez-Veiga, Rebeca; Salamero, Olga; Sanz, Jaime et al.
DOI: 10.1007/s00277-013-1914-y

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

PMID: 24401928
Journal: ANN ONCOL
Year: 2014
Reference: Ann Oncol. 2014 Mar;25(3):592-8. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8.
Impact factor: 6.578
Publication type: Clinical Trials
Authors: Baselga, J, Manikhas, A, Cortes, J, Llombart, A, Roman, L, Semiglazov, V F, Byakhov, M, Lokanatha, D, Forenza, S, Goldfarb, R H et al.
DOI: 10.1093/annonc/mdt543

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

PMID: 24401928
Journal: ANNALS OF ONCOLOGY
Year: 2014
Reference: Ann Oncol. 2014 Mar;25(3):592-8. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8.
Impact factor:
Publication type: Clinical Trials
Authors: Azarnia, N; Baselga, J; Byakhov, M; Cortes, J; Forenza, S; Goldfarb, R H; Hudis, C A; Llombart, A; Lokanatha, D; Manikhas, A et al.
DOI: 10.1093/annonc/mdt543

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

PMID: 25193991
Journal: ANN ONCOL
Year: 2014
Reference: Ann Oncol. 2014 Nov;25(11):2244-51. doi: 10.1093/annonc/mdu390. Epub 2014 Sep 5.
Impact factor: 6.578
Publication type: Clinical Trials
Authors: Robert, R, D'Incalci, M, Zucchetti, M, Camboni, M G, Tabernero, J, Saba, C, Dubois, F, Allen, A, Litten, J, Soria, J-C et al.
DOI: 10.1093/annonc/mdu390

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

PMID: 25193991
Journal: ANNALS OF ONCOLOGY
Year: 2014
Reference: Ann Oncol. 2014 Nov;25(11):2244-51. doi: 10.1093/annonc/mdu390. Epub 2014 Sep 5.
Impact factor:
Publication type: Clinical Trials
Authors: Adamo, B; Allen, A; Andre, F; Bahleda, R; Camboni, M G; Cereda, R; D'Incalci, M; DeBraud, F; Delmonte, A; Dientsmann, R et al.
DOI: 10.1093/annonc/mdu390

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

PMID: 24997153
Journal: HAEMATOLOGICA
Year: 2014
Reference: Haematologica. 2014 Oct;99(10):1632-7. doi: 10.3324/haematol.2014.105908. Epub 2014 Jul 4.
Impact factor: 5.868
Publication type: Clinical guide
Authors: Valcarcel, David, Jarque, Isidro, Jimenez, Santiago, Rovira, Montserrat, Lopez, Javier, Hernandez, Dolores, Vallejo, Carlos, Batlle, Montserrat, Vazquez, Lourdes, Solano, Carlos et al.
DOI: 10.3324/haematol.2014.105908